A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

被引：0
|
作者：
Kenjiro Aogi
Hiroshi Sakai
Hirohisa Yoshizawa
Norikazu Masuda
Nobuyuki Katakami
Yasuhiro Yanagita
Kenichi Inoue
Masaru Kuranami
Mitsuhiro Mizutani
Noriyuki Masuda
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Breast Oncology
[2] Saitama Cancer Center,Department of Thoracic Oncology
[3] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
[4] National Hospital Organization Osaka National Hospital,Department of Surgery
[5] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
[6] Gunma Cancer Center,Department of Breast Oncology
[7] Saitama Cancer Center,Department of Breast Oncology
[8] Kitasato University School of Medicine,Department of Surgery
[9] Aichi Cancer Center Aichi Hospital,Department of Breast Surgery
[10] Kitasato University School of Medicine,Department of Respiratory Medicine
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Palonosetron; 5-HT; receptor antagonist; Antiemetic; Chemotherapy-induced nausea and vomiting; Highly emetogenic chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1507 / 1514
页数：7
相关论文
共 50 条
  • [41] Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
    Kurteva, Galina
    Chilingirova, Nataliya
    Rizzi, Giada
    Caccia, Tatiana
    Stell, Valentino
    Bernareggi, Alberto
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 139
  • [42] Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting
    Wang, Nan
    Xu, Peng
    Liu, Yu
    Zhao, Peng
    Ruan, Jian
    Zheng, Yi
    Jin, Junpei
    Wang, Shuqian
    Yao, Jia
    Xiang, Dong
    Zhang, Dai
    Li, Na
    Kang, Huafeng
    Dai, Zhijun
    JOURNAL OF CANCER, 2020, 11 (15): : 4560 - 4570
  • [43] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
    Gralla, R
    Lichinitser, M
    Van der Vegt, S
    Sleeboom, H
    Mezger, J
    Peschel, C
    Tonini, G
    Labianca, R
    Macciocchi, A
    Aapro, M
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577
  • [44] Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Schwartzberg, Lee
    Barbour, Sally Y.
    Morrow, Gary R.
    Ballinari, Gianluca
    Thorn, Michael D.
    Cox, David
    SUPPORTIVE CARE IN CANCER, 2014, 22 (02) : 469 - 477
  • [45] Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
    Miya, Toshimichi
    Kobayashi, Kunihiko
    Hino, Mitsunori
    Ando, Masahiro
    Takeuchi, Susumu
    Seike, Masahiro
    Kubota, Kaoru
    Gemma, Akihiko
    SPRINGERPLUS, 2016, 5
  • [46] Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
    Lee Schwartzberg
    Sally Y. Barbour
    Gary R. Morrow
    Gianluca Ballinari
    Michael D. Thorn
    David Cox
    Supportive Care in Cancer, 2014, 22 : 469 - 477
  • [47] NEPA <sc>(</sc>Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
    Navari, Rudolph M.
    Bonizzoni, Erminio
    CANCER MEDICINE, 2025, 14 (07):
  • [48] A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chang, J.
    Wang, D.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 452 - 458
  • [49] Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
    Hesketh, P. J.
    Rossi, G.
    Rizzi, G.
    Palmas, M.
    Alyasova, A.
    Bondarenko, I.
    Lisyanskaya, A.
    Gralla, R. J.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1340 - 1346
  • [50] Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
    Celio, Luigi
    Niger, Monica
    Ricchini, Francesca
    Agustoni, Francesco
    CORE EVIDENCE, 2015, 10 : 75 - 87
12345